Keywords: UK, NICE, Multiple sclerosis, Avonex, Betaferon, Rebif, Copaxone, Tysabri
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
Article | 3 December 2009
In 2002, the UK’s National Institute for Clinical Excellence (NICE) ruled that certain drugs for the treatment of multiple sclerosis were not cost effective. In response, the Department of Health set up an observational study called the Risk Sharing Scheme.
The aim of the study was to observe the effects of these drugs (over a 10-year period) and if the four drugs in question failed to perform as promised then the manufacturers would share the risk of any potential negative outcomes by subsidising their future cost to the National Health Service. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
